Amarna's next-generation viral vector platform promises to transform treatment across many disease areas
Amarna Therapeutics, founded in 2008, is a privately held Biotech company that developed the SVac viral gene delivery vector platform, the key to the success of next stage gene and immune-therapies. SVac is safe, highly efficient, non-immunogenic and vector particles can be produced cost effectively in our SuperVero packaging cell line.
Because of its safety, efficacy and non-immunogenicity in humans our SVac platform has highly promising qualities for treating the major diseases of our time, creating opportunities to serve the major pharmaceutical markets.
Oct 16, 2019
Amarna Therapeutics Raises €10 million to Progress lead Development Candidate into Clinical Trials and Appoints a new Supervisory Board
When something is important enough, you do it even if the odds are not in your favor.
Among other things, autoimmune disorders are an induction into a world of unstable information and no reliable expertise.
I hope that the image of gene therapy is changing. It seems to be.
SVac paves the way to clinically evaluate a whole new generation of SV40-based therapeutics for a broad range of important diseases.
Some people don't like change, but you need to embrace change if the alternative is disaster.
It’s your immune system, and it’s attacking you: physical self-loathing, a civil war in the body. The medical community frequently shrugs away the deeper questions. Doctors will treat the symptoms, but as for why your immune system would do this—burn down its own house—that’s a mystery.
In the past, when we've tried gene therapy, we haven't had tools that have allowed targeted gene correction.
SVac is safe, highly efficient, non-immunogenic and vector particles can be produced cost effectively in our SuperVero packaging cell line.